DocJuris has raised a $8 million series A. Photo via Getty Images

Houston-based DocJuris, a leader in AI contract review, announced the successful closure of its series A funding round by raising $8 million in new capital. This brings the total capital raised to date to $11.2 million.

"DocJuris AI has become an industry-leading platform that empowers enterprise legal, procurement, and sales teams to close deals faster while reducing risk," DocJuris CEO and Founder Henal Patel says in a news release. "With this funding, we will continue scaffolding our platform around generative AI, expand our customer success team, and grow our user base."

The most active venture capital firm in Texas Silverton Partners led the round with participation from previous investors Watertower Ventures, Surface Ventures, and Seed Round Capital.

Companies like Siemens, Dell, FedEx, Toyota, and Duke Energy already use DocJuris with its AI-powered contract negotiation software that automates imporrant tasks during the review, redlining, and negotiation of contracts. DocJuris uses a platform to screen third-party contracts in seconds, can redline clauses with playbook-compliant edits in one click, and also generate formatted track changes, exception tables, and amendments with a cloud-based application.

The Association of Corporate Counsel, awarded DocJuris the Value Champion Award in 2023 due to the reduced contract cycle times to minutes with AI.

“We wanted to replace repetitive, manual tasks and free up valuable time for our employees to focus on more impactful work,” lead attorney for Flex's Global Procurement and Supply Chain Iringo Csifo-Nagy adds. “To achieve this, we developed a turnkey solution for AI-driven contract reviews together with the DocJuris team."

In its first round of funding in 2021, DocJuris raised $3.2 million in seed capital.

DocJuris has raised its first round of venture funding to grow its team to keep up with demand for its legal software platform. Image courtesy of DocJuris

Houston B2B software company raises $3.2M in seed funding to grow team and product

money moves

A Houston-based software-as-a-service company that is revolutionizing the contract process has closed a round of funding this week.

DocJuris, founded in 2018, raised $3.2 million in seed funding led by New York-based RTP Seed with additional support from Houston-based Seed Round Capital, California-based Watertower Ventures, Maryland-based Crossbeam, and Remote First Capital.

It's the startup's first round of venture funding and Henal Patel, CEO of DocJuris, says he was looking for funds as well as support from investors who had experience with software and could open doors to new clients for the legal software.

"Our platform is designed to empower legal, sales, and procurement teams and corporations to negotiate and close contracts with greater speed and precision," Patel says. "The underlying mission is to solve the last-mile of contracting."

Henal Patel is CEO of DocJuris. Photo courtesy of DocJuris

The need for funding came at a time of growth, Patel says, as DocJuris was seeing more and more opportunities in light of the pandemic.

"As work has gone more remote, there's a greater need for teams to be able to collaborate on their contracts — instead of sending Word documents over email," he tells InnovationMap.

Within the contract optimization space, Patel says he sees a lot of opportunities for enhancing the experience for lawyers, business owners, contractors, and anyone who has to spend any amount of time on legal papers.

"One of our visions is to — in addition to providing the tactical tools we do to day — revisualize the way that people read contracts," Patel says. "Our platform enables the ability to improve the lives of the people who have to stare at contracts all day."

DocJuris is already hiring for a few positions across sales, customer service, and marketing, and Patel says he will continue to grow his remote team locally.

"We've been remote since before it was cool," Patel says, adding that all but one of his employees is based in Houston. "But we've been locally concentrated in Houston. We're planning on growing our team here in Houston, but keeping the team remote. We believe in Houston."

This week's Houston innovators to know includes Chris Buckner of Mainline and Austin Hill and Brad Jenkins of Seed Round Capital. Photos courtesy

3 Houston innovators to know this week

who's who

This week's Houston innovators to know have all grown or started a company during the COVID-19 pandemic — a bold choice. From an esports software entrepreneur to two serial founders looking to invest in the next generation of Houston tech startups.

Chris Buckner, co-founder and CEO of Mainline

With sports offline, esports startup Mainline has seen an opportunity for growth during the COVID-19 outbreak. Photo courtesy of Mainline

While Chris Buckner has found the isolation aspect of the pandemic challenging, he shares on this week's episode of the Houston Innovators Podcast that it's actually been an extremely exciting time for his esports tournament software startup, Mainline. This year, Mainline is poised to onboard over 100 schools to their system, and, while most of those schools were lined up before the pandemic, the process has been sped up.

"Everyone is looking for how to get sports, or esports, in front of people because everyone is just missing [sports] so much," Buckner says. "We've been very fortunate to work in the industry we do."

On campuses this past spring, basketball was cut short, baseball was canceled, and football's status is currently unknown. Colleges are looking for a way to connect with and engage students, Buckner says. And, Mainline has even been able to attract interest on the professional level. Read more and strea

Austin Hill and Brad Jenkins, co-founders of Seed Round Capital

Brad Jenkins and Austin Hill have announce the launch of a growth and invetment-focused incubator for startups called Seed Round Capital. Photos courtesy of Seed Round Capital

Brad Jenkins and Austin Hill wanted to create a firm that prioritized funding for growing tech startups in Houston, so they teamed up to launch Seed Round Capital, an investment and advisory firm based in Houston and for Houston-based startups. Rather than an accelerator model, the new firm will focus on long-term support for its portfolio companies.

"Our program helps startup founders fund and scale their businesses with management guidance from seasoned entrepreneurs. In addition, founders receive training on proven business methods specially formulated by Seed Round Capital, and access to funding," Hill says in a statement to InnovationMap.

Startups can apply online to be selected to receive mentoring from Jenkins, Hill, and a network of experts involved in — or previously involved in — Entrepreneurs' Organization (EO), a local group of business leaders. Once selected, Seed Round's startups will have access to office space at The Cannon. Read more.

Brad Jenkins and Austin Hill have announce the launch of a growth and invetment-focused incubator for startups called Seed Round Capital. Photos courtesy of Seed Round Capital

Exclusive: 2 serial entrepreneurs launch Houston startup incubator

funding focused

Two Houstonians with years of entrepreneurial and investing experience are starting a firm focused on advising and growing local technology startups.

Brad Jenkins and Austin Hill have announced the launch of Seed Round Capital, an investment and advisory firm based in Houston and for Houston-based startups. Rather than an accelerator model, the new firm will focus on long-term support for its portfolio companies.

"Our program helps startup founders fund and scale their businesses with management guidance from seasoned entrepreneurs. In addition, founders receive training on proven business methods specially formulated by Seed Round Capital, and access to funding," Hill says in a statement to InnovationMap.

Startups can apply online to be selected to receive mentoring from Jenkins, Hill, and a network of experts involved in — or previously involved in — Entrepreneurs' Organization (EO), a local group of business leaders. Once selected, Seed Round's startups will have access to office space at The Cannon.

"Because we recognize that every new business is unique in its journey, we are able to customize mentoring to suit each startup. Our expertise helps startups reduce risk, secure funding and grow faster than if they were doing this on their own," Jenkins says.

Jenkins has 25 years of software and technology startup experience and has served on the Houston board of EO. A Texas A&M University alumnus, he has a background in marketing and computer science. Hill's specialty includes distribution, contracting, real estate, and consumer-packaged goods. A University of Texas and West Point graduate, he won Rice University's Veterans Business Battle competition and organizes the EO's accelerator program.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”